Inclusion Criteria:

- Signed informed consent

- Age > 18 years

- Confirmed melanoma

- Patient has been prescribed Intron A therapy for High-Risk Stage II & III Melanoma

- Intron A therapy started within 70 days of surgery (additional 15 days may be granted
by the sponsor upon written approval)

- Proper contraception in both male and female subjects and the female partner(s) of
male study subjects

Exclusion Criteria:

- Metastatic disease at the time of diagnosis

- Other malignancies

- History of non compliance to other therapies

- Pregnancy or breast feeding

- Previous Intron A therapy